1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024

EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024

Summary

Head and neck cancers (HNCs) are a heterogeneous group, consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth; the salivary glands; the pharynx, including the tonsil, oropharynx, nasopharynx, pyriform fossa, hypopharynx, other mouth/pharynx; the nose, sinuses, and related structures; the larynx; and the thyroid. HNCs usually begin in the squamous cells that line the moist mucosal surfaces of the tissues and organs of the head and neck — more than 80% of all HNCs are squamous cell carcinomas. HNCs are common in several regions across the globe and account for 600,000 new cases annually worldwide.

GlobalData epidemiologists forecast an increase in diagnosed incident cases of HNCs in the 7MM from 151,393 diagnosed incident cases in 2014 to 174,056 diagnosed incident cases in 2024, with an Annual Growth Rate (AGR) of 1.50% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of HNCs in the 7MM, with 65,663 diagnosed incident cases, whereas the UK will have the lowest number of diagnosed incident cases of HNCs, with 12,702 diagnosed incident cases in 2024. The diagnosed incident cases of thyroid cancer in the 7MM are expected to increase from 93,225 diagnosed incident cases in 2014 to 123,504 diagnosed incident cases in 2024, with an AGR of 3.25% during the forecast period. In 2024, the US will have the highest number of diagnosed incident cases of thyroid cancer in the 7MM with 81,286 diagnosed incident cases, whereas Spain will have the lowest number of diagnosed incident cases of thyroid cancer with 3,233 diagnosed incident cases in 2024.

Scope

- The Head and neck cancers (HNCs) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for HNCs in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed incident cases of HNCs segmented into three sub-groups: cancers of the lip, oral cavity, and pharynx; cancers of the nose, sinuses, and related structures; and cancers of the larynx, in these markets. It also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of HNCs (excluding nose, sinuses, and related cancers). Additionally, it includes a 10-year epidemiological forecast for the diagnosed incident cases and the five-year diagnosed prevalent cases of thyroid cancer in the 7MM. The diagnosed incident cases of HNCs (excluding nose, sinuses, and related cancers) and thyroid cancer are segmented by age, sex, clinical stage at diagnosis, and histology.
- The HNCs epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The HNCs EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global HNCs market.
- Quantify patient populations in the global HNCs market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for HNCs therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Head and Neck Cancers - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Reports 12
3 Epidemiology 13
3.1 Disease Background 13
3.2 Risk Factors and Comorbidities 15
3.3 Global Trends 17
3.3.1 Incidence 17
3.3.2 Relative Survival - 7MM 21
3.4 Forecast Methodology 23
3.4.1 Sources Used 28
3.4.2 Sources Not Used 31
3.4.3 Forecast Assumptions and Methods 31
3.5 Epidemiological Forecast for HNCs and Thyroid Cancer (2014-2024) 34
3.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 34
3.5.2 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers 35
3.5.3 Diagnosed Incident Cases of Larynx Cancer 37
3.5.4 Diagnosed Incident Cases of HNCs 38
3.5.5 Diagnosed Incident Cases of Thyroid Cancer 40
3.5.6 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 41
3.5.7 Age-Specific Diagnosed Incident Cases of Larynx Cancer 43
3.5.8 Age-Specific Diagnosed Incident Cases of Thyroid Cancer 45
3.5.9 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 47
3.5.10 Sex-Specific Diagnosed Incident Cases of Larynx Cancer 49
3.5.11 Sex-Specific Diagnosed Incident Cases of Thyroid Cancer 51
3.5.12 Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, and Pharynx Cancer 53
3.5.13 Age-Standardized Diagnosed Incidence of Larynx Cancer 55
3.5.14 Age-Standardized Diagnosed Incidence of Thyroid Cancer 56
3.5.15 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis 57
3.5.16 Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis 58
3.5.17 Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis 58
3.5.18 Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution 59
3.5.19 Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution 60
3.5.20 Diagnosed Incident Cases of Larynx Cancer by Histology Distribution 61
3.5.21 Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution 62
3.5.22 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer 63
3.5.23 Five-Year Diagnosed Prevalent Cases of Larynx Cancer 65
3.5.24 Five-Year Diagnosed Prevalent Cases of Thyroid Cancer 67
3.6 Discussion 68
3.6.1 Epidemiological Forecast Insight 68
3.6.2 Limitations of the Analysis 69
3.6.3 Strengths of the Analysis 69
4 Appendix 71
4.1 Bibliography 71
4.2 About the Authors 75
4.2.1 Epidemiologists 75
4.2.2 Reviewers 75
4.2.3 Global Director of Therapy Analysis and Epidemiology 76
4.2.4 Global Head of Healthcare 77
4.3 About GlobalData 78
4.4 About EpiCast 78
4.5 Disclaimer 79

1.1 List of Tables
Table 1: HNCs Clinical Stages at Diagnosis 14
Table 2: Risk Factors for HNCs 17
Table 3: Trends in the Age-Adjusted Incidence of Lip, Oral Cavity, and Pharynx Cancer in the 7MM, All Ages, 1998-2007 18
Table 4: Trends in the Age-Adjusted Incidence of Larynx Cancer in the 7MM, All Ages, 1998-2007 19
Table 5: Trends in the Age-Adjusted Incidence of Thyroid Cancer in the 7MM, All Ages, 1998-2007 20
Table 6: Trends in the Five-Year Relative Survival (%) of HNCs and Thyroid Cancer in the 7MM, Both Sexes, 1993-2007 22
Table 7: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer 23
Table 8: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Larynx Cancer 23
Table 9: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer 24
Table 10: 7MM, Sources of Epidemiological Data Used for the Forecast for the Diagnosed Incident Cases of Thyroid Cancer 24
Table 11: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer 25
Table 12: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Larynx Cancer 25
Table 13: 7MM, Sources of Epidemiological Data Used for the Forecast for the Five-Year Diagnosed Prevalent Cases of Thyroid Cancer 26
Table 14: 7MM, Sources of Epidemiological Data Used for the Segmentation of Diagnosed Incident Cases of HNCs (Excluding Nose, Sinuses, and Related Cancers) and Thyroid Cancer by Clinical Stage at Diagnosis 27
Table 15: 7MM, Sources of Epidemiological Data Used for the Segmentation of the Diagnosed Incident Cases HNCs and Thyroid Cancer by Histology Distribution 28
Table 16: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024 34
Table 17: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024 36
Table 18: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024 37
Table 19: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014-2024 39
Table 20: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024 40
Table 21: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N (Row %), 2014 42
Table 22: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N (Row %), 2014 44
Table 23: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N (Row %), 2014 46
Table 24: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N (Row %), 2014 48
Table 25: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N (Row %), 2014 50
Table 26: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N (Row %), 2014 52
Table 27: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024 64
Table 28: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024 66
Table 29: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024 67

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, All Ages, N, 2014-2024 35
Figure 2: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancer, Both Sexes, All Ages, N, 2014-2024 36
Figure 3: 7MM, Diagnosed Incident Cases of Larynx Cancer, Both Sexes, All Ages, N, 2014-2024 38
Figure 4: 7MM, Diagnosed Incident Cases of HNCs, Both Sexes, All Ages, N, 2014-2024 39
Figure 5: 7MM, Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, All Ages, N, 2014-2024 41
Figure 6: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, Both Sexes, N, 2014 43
Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of Larynx Cancer, Both Sexes, N, 2014 45
Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Thyroid Cancer, Both Sexes, N, 2014 47
Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, N, 2014 49
Figure 10: 7MM, Sex-Specific Diagnosed Incident Cases of Larynx Cancer, All Ages, N, 2014 51
Figure 11: 7MM, Sex-Specific Diagnosed Incident Cases of Thyroid Cancer, All Ages, N, 2014 53
Figure 12: 7MM, Age-Standardized Diagnosed Incidence Cases of Lip, Oral Cavity, and Pharynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014 54
Figure 13: 7MM, Age-Standardized Diagnosed Incidence Cases of Larynx Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014 55
Figure 14: 7MM, Age-Standardized Diagnosed Incidence Cases of Thyroid Cancer (Cases per 100,000 Population), All Ages, by Sex, 2014 56
Figure 15: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 57
Figure 16: 7MM, Diagnosed Incident Cases of Larynx Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 58
Figure 17: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Clinical Stage at Diagnosis, All Ages, Both Sexes, N, 2014 59
Figure 18: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, and Pharynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014 60
Figure 19: 7MM, Diagnosed Incident Cases of Nose, Sinuses, and Related Cancers by Histology Distribution, All Ages, Both Sexes, N, 2014 61
Figure 20: 7MM, Diagnosed Incident Cases of Larynx Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014 62
Figure 21: 7MM, Diagnosed Incident Cases of Thyroid Cancer by Histology Distribution, All Ages, Both Sexes, N, 2014 63
Figure 22: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, and Pharynx Cancer, All Ages, Both Sexes, N, 2014-2024 65
Figure 23: 7MM, Five-Year Diagnosed Prevalent Cases of Larynx Cancer, All Ages, Both Sexes, N, 2014-2024 66
Figure 24: 7MM, Five-Year Diagnosed Prevalent Cases of Thyroid Cancer, All Ages, Both Sexes, N, 2014-2024 68

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

Download Unlimited Documents from Trusted Public Sources

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Related Market Segments :

Cancer

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.